RXRX

RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025)

Recursion Pharmaceuticals (NASDAQ: RXRX), one of the highest‑profile AI‑driven drug discovery names, is back under the microscope. As of the December 5, 2025 close, RXRX stock traded around $4.71, giving the company a market capitalization of roughly $2.5 billion and

7 December 2025

Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025

Snapshot: Where RXRX Stands Going Into the New Week Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) closed Friday, November 21, 2025, at $4.17, up 8.31% on the day after bouncing off the low‑$3 range earlier in the week. Volume was heavy at

24 November 2025

Artificial Intelligence · Institutional Investors · Investing · Pharmaceuticals · Stock Market

AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharma Stock Soars 16% on AI Buzz and Big Pharma Deals – Can RXRX Keep Climbing?

Stock Soars on Oct 20 Amid Wild October Trading Recursion’s stock is on a rollercoaster ride this month. Early on October 20, RXRX surged ~16–18%, hitting intraday highs near $6.8 benzinga.com. The rally comes after shares slid 7.9% on Friday

20 October 2025

Artificial Intelligence · Investing · Market News · Pharmaceuticals · Stocks

Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Volatile Stock Performance in October 2025 Recursion’s stock showed wild swings in early October. On Oct 7, 2025 the shares fell about 5.4% to ~$5.23 amid a broad market slump nasdaq.com. The very next day (Oct 8) the stock rebounded

15 October 2025

Artificial Intelligence · Biotechnology · Investment Trends · NASDAQ:RXRX · Pharma Industry · Stock Market